Mineralocorticoid Receptor Antagonist

An op-ed published in February by Tom Frieden, MD, MPH, former director of the CDC, described hypertension as “the deadliest but most neglected and widespread pandemic of our time” — and he’s right.

Initiation of the nonsteroidal mineralocorticoid receptor antagonist eplerenone shows benefit in patients with HF with reduced ejection fraction, regardless of their disease duration, 1 year or more than 5 years, a speaker reported.

PHILADELPHIA — In patients with HF with reduced ejection fraction, the four pillars of optimal medical therapy should be started as soon as possible, a speaker said here.

Rapid uptitration of medical therapy early after hospitalization for acute HF improves prognosis independent of left ventricular ejection fraction, according to a prespecified analysis of the STRONG-HF trial.

Two methods of informing providers when a patient with HFrEF is not on appropriate medical therapy — EHR alerts during patient encounters and messages in between encounters — vs. usual care.

Defining eligibility criteria for initiation of guideline-directed medical therapy and new HF agents.

NEW ORLEANS — An automated, patient-specific, electronic health record-embedded tool was associated with increased prescriptions of mineralocorticoid receptor antagonists for patients with HF, the BETTER CARE-HF study showed.

The majority of patients admitted for acute HF are eligible for foundational quadruple therapy and other medications, researchers reported in JACC: Heart Failure.

The benefits of HF medications are additive and incremental and provide similar benefits to patients with ischemic and nonischemic etiologies when initiated simultaneously, according to a speaker.

Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial outcomes in several renin-angiotensin-aldosterone system-mediated disease states.